NP / PA
Berkowitz, Laureen
Berkowitz, Laureen was paid $233K by Medicaid between Mar 2018 and Apr 2024, across 15 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 25% of everything it billed.
33Billing provider infoBERKOWITZ, LAUREEN
PROVIDENCE, RI 02904
PROVIDENCE, RI 02904
33aNPI1104110030assigned 06/08/2011
33bProvider typePhysician Assistant
28Total paid$233K
24GClaims3,449
24DCodes billed15
24AFirst – last monthMar 2018 – Apr 2024
Compared with peers
Next to other Physician Assistant providers in Rhode Island
Rank by total paid#15 of 215
Median peer was paid$17K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 528 | $40K | |
| 2019 | 158 | $11K | |
| 2020 | 777 | $44K | |
| 2021 | 1,283 | $64K | |
| 2022 | 115 | $9K | |
| 2023 | 436 | $52K | |
| 2024incomplete | 152 | $13K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 891 | 764 | $59K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 569 | 426 | $37K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 16% | 111 | 93 | $37K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 9.3% | 291 | 217 | $22K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 6.8% | 772 | 514 | $16K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 6.7% | 145 | 118 | $16K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.8% | 90 | 60 | $14K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.7% | 88 | 61 | $13K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.5% | 131 | 106 | $11K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.4% | 67 | 61 | $3K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.1% | 36 | 33 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 69 | 66 | $2K |
3 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.